GeneDx Holdings Corp vs Wipro Limited — how do they compare? GeneDx Holdings Corp trades at $80.81 (market cap $2.32B), while Wipro Limited trades at $1.98 (market cap $19.22B). The key difference: Wipro Limited is far larger — about 8.3× GeneDx Holdings Corp's market cap, and Wipro Limited pays a 4.35% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| WGS | WIT | |
|---|---|---|
Market Cap | $2.32B | $19.22B |
Sector | Technology | Technology |
52-Week High | $167.51 | $3.06 |
52-Week Low | $34.51 | $1.78 |
Enterprise Value | $2.35B | $17.30B |
Dividend Yield | — | 4.35% |
Signals from Pluang's Aura AI — not financial advice
GeneDx Holdings Corp. (WGS) trades at $77.08, up 10.76% today, showing strong momentum despite negative profitability metrics. The stock exhibits bullish technical signals with support at $72 and resistance at $80. Recent Q2 2026 earnings beat expectations with $0.01 EPS versus -$0.19 estimate, while revenue reached $114.4 million. However, the company faces significant challenges with a -23.4% net income margin and ongoing securities class action litigation.
Investment outlook remains cautiously optimistic given strong analyst support (90.9% buy rating) and $79.25 consensus price target. Key opportunities include growing genomic testing volumes and improved operational efficiency, while risks center on profitability challenges, legal liabilities, and high valuation multiples that may not justify current fundamentals.
WIT trades at $2.02, up 1.51% today, with a neutral technical signal and bearish moving average trend. The company reported a net income margin of 13.92% and ROE of 16.09% for 2025, with revenue of $890.88 billion. Recent earnings have missed expectations, but partnerships with Databricks and ServiceNow aim to drive AI-led growth. Cash flow from operations remains strong at $169.43 billion, supporting a $0.02 dividend.
The outlook is mixed: valuation ratios like P/E of 15.25 and EV/EBITDA of 7.83 appear reasonable, but earnings misses and competitive pressures pose risks. Analyst sentiment is cautious with only 19% buy ratings. Key opportunities include AI expansion, while risks involve client spending cuts and margin pressure from wage increases.
Trailing returns across standard periods
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →Wipro is a leading global IT services provider, with 175,000 employees. Based in Bengaluru, this India IT services firm leverages its offshore outsourcing model to derive over half of its revenue (57%) from North America. The company offers traditional IT services offerings: consulting, managed services, and cloud infrastructure services as well as business process outsourcing as a service.
Read more on WIT →